# Treprostinil

Drug · id `cardio:treprostinil` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Remodulin; TYVASO; Orenitram; Treprostinil sodium; Treprostinil diolamine

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Treprostinil is a prostacyclin mimetic. This page records what three US labels from one sponsor say, one for each route. The label for Remodulin, an injection formulated for subcutaneous or intravenous administration, lists pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise and, separately, for patients who require transition from epoprostenol, reducing the rate of clinical deterioration. The label for Tyvaso, a sterile solution for oral inhalation, lists PAH to improve exercise ability and, separately, pulmonary hypertension associated with interstitial lung disease (WHO Group 3) to improve exercise ability. The label for Orenitram, extended-release tablets, lists PAH to delay disease progression and to improve exercise capacity. Each statement belongs to its own label and route.

## Technical summary

RxNorm ingredient 343048; UNII RUM6K67ESG. MeSH has no descriptor for treprostinil (name lookups on 2026-11-18 found only supplementary concept terms), so no MeSH identifier is recorded. RxClass lists the established pharmacologic class spelled Prostacycline Vasodilator, so the record is filed under the prostacyclin pathway page. The labels read, all by United Therapeutics Corporation, are Remodulin (NDA021272, effective 2026-07-02 in openFDA), Tyvaso (NDA022387, effective 2026-04-14) and Orenitram (NDA203496, effective 2024-11-20). Other treprostinil products and labels, including other inhaled products, were not read. Drugs@FDA lists the ingredient strings treprostinil, treprostinil sodium and treprostinil diolamine; the two salt names are kept as aliases. The statements sit in separate claims and contexts, and none gives a dose or an instruction.

## Claims, with the population each applies to

## Context: Patients with pulmonary arterial hypertension, as described in the US label of Orenitram

Recipient: Recipient not specified; Population: Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the label states. The passage read gives no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Orenitram (treprostinil extended-release tablets, United Therapeutics Corporation, application NDA203496; the version dated 2024-11-20 in openFDA) calls the medicine a prostacyclin mimetic. It lists treating pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the label states. The passage read gives no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim is tied to the Orenitram tablet label only. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Orenitram (treprostinil extended-release tablets), United Therapeutics Corporation label: indications and dosage forms (Regulator, edition The openFDA drug label record for set id 8ed2003a-c801-411e-831e-d06079bb0d7c (manufacturer United Therapeutics Corporation, application NDA203496), returned on 2026-11-18. The label text is dated 2024-11-20 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228ed2003a-c801-411e-831e-d06079bb0d7c%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-19T02:47:45Z. Source state: Current. Version fingerprint: d8a098270f8df7a60f3ab00c587921a8e61696526f26db8b624881165be822b0.
     How it applies: Application number of the label read, NDA203496.
  2. Background: openFDA drug label record for Orenitram (treprostinil extended-release tablets), United Therapeutics Corporation label: indications and dosage forms (Regulator, edition The openFDA drug label record for set id 8ed2003a-c801-411e-831e-d06079bb0d7c (manufacturer United Therapeutics Corporation, application NDA203496), returned on 2026-11-18. The label text is dated 2024-11-20 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228ed2003a-c801-411e-831e-d06079bb0d7c%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-19T02:47:45Z. Source state: Current. Version fingerprint: d8a098270f8df7a60f3ab00c587921a8e61696526f26db8b624881165be822b0.
     How it applies: Effective date of the label text read, 20241120.
  3. Supports: openFDA drug label record for Orenitram (treprostinil extended-release tablets), United Therapeutics Corporation label: indications and dosage forms (Regulator, edition The openFDA drug label record for set id 8ed2003a-c801-411e-831e-d06079bb0d7c (manufacturer United Therapeutics Corporation, application NDA203496), returned on 2026-11-18. The label text is dated 2024-11-20 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228ed2003a-c801-411e-831e-d06079bb0d7c%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-19T02:47:45Z. Source state: Current. Version fingerprint: d8a098270f8df7a60f3ab00c587921a8e61696526f26db8b624881165be822b0.
     How it applies: Label passage quoted in the research quote table (Q-K30-TRE-OR-03, Q-K30-TRE-OR-04, Q-K30-TRE-OR-05).

## Context: Patients with pulmonary arterial hypertension who require transition from epoprostenol, as described in the US label of Remodulin

Recipient: Recipient not specified; Population: Patients who require transition from epoprostenol, as the label states. The passage read gives no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label of Remodulin separately lists, for patients who require transition from epoprostenol, reducing the rate of clinical deterioration.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients who require transition from epoprostenol, as the label states. The passage read gives no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim is tied to the Remodulin injection label only, and to the transition use the label names. It does not say how a transition is done, and no instruction is recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%226c80bb38-e8db-4138-9f0d-dbbf9c673185%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:40Z. Source state: Current. Version fingerprint: 8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0.
     How it applies: Application number of the label read, NDA021272.
  2. Background: openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%226c80bb38-e8db-4138-9f0d-dbbf9c673185%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:40Z. Source state: Current. Version fingerprint: 8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0.
     How it applies: Effective date of the label text read, 20260702.
  3. Supports: openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%226c80bb38-e8db-4138-9f0d-dbbf9c673185%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T22:01:40Z. Source state: Current. Version fingerprint: 8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0.
     How it applies: Label passage quoted in the research quote table (Q-K30-TRE-RE-05).

## Context: Patients with pulmonary arterial hypertension, as described in the US label of Remodulin

Recipient: Recipient not specified; Population: Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Remodulin (treprostinil injection, United Therapeutics Corporation, application NDA021272; the version dated 2026-07-02 in openFDA) calls the medicine a prostacyclin mimetic, formulated for subcutaneous or intravenous administration. It lists treating pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim is tied to the Remodulin injection label only. The inhaled and oral treprostinil products have their own labels and claims. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a transition use, which sits in a separate claim.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%226c80bb38-e8db-4138-9f0d-dbbf9c673185%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:40Z. Source state: Current. Version fingerprint: 8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0.
     How it applies: Application number of the label read, NDA021272.
  2. Background: openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%226c80bb38-e8db-4138-9f0d-dbbf9c673185%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:40Z. Source state: Current. Version fingerprint: 8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0.
     How it applies: Effective date of the label text read, 20260702.
  3. Supports: openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%226c80bb38-e8db-4138-9f0d-dbbf9c673185%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T22:01:40Z. Source state: Current. Version fingerprint: 8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0.
     How it applies: Label passage quoted in the research quote table (Q-K30-TRE-RE-03, Q-K30-TRE-RE-04, Q-K30-TRE-RE-06).

## Context: Patients with pulmonary arterial hypertension, as described in the US label of Tyvaso

Recipient: Recipient not specified; Population: Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Tyvaso (treprostinil, a sterile solution for oral inhalation, United Therapeutics Corporation, application NDA022387; the version dated 2026-04-14 in openFDA) calls the medicine a prostacyclin mimetic. It lists treating pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim is tied to the Tyvaso inhalation solution label only. Other inhaled treprostinil products have their own labels and were not read. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists pulmonary hypertension with interstitial lung disease, which sits in a separate claim.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism (Regulator, edition The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22cbc31ab1-a80f-4b50-a3b1-39910b0fb609%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-19T02:47:45Z. Source state: Current. Version fingerprint: 3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd.
     How it applies: Application number of the label read, NDA022387.
  2. Background: openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism (Regulator, edition The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22cbc31ab1-a80f-4b50-a3b1-39910b0fb609%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-19T02:47:45Z. Source state: Current. Version fingerprint: 3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd.
     How it applies: Effective date of the label text read, 20260414.
  3. Supports: openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism (Regulator, edition The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22cbc31ab1-a80f-4b50-a3b1-39910b0fb609%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-19T02:47:45Z. Source state: Current. Version fingerprint: 3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd.
     How it applies: Label passage quoted in the research quote table (Q-K30-TRE-TY-03, Q-K30-TRE-TY-04, Q-K30-TRE-TY-06).

## Context: Patients with pulmonary hypertension associated with interstitial lung disease, as described in the US label of Tyvaso

Recipient: Recipient not specified; Population: Patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), as the label states. The passage read gives no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label of Tyvaso separately lists treating pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), as the label states. The passage read gives no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim is tied to the Tyvaso inhalation solution label only, and concerns a different group of pulmonary hypertension from pulmonary arterial hypertension. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism (Regulator, edition The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22cbc31ab1-a80f-4b50-a3b1-39910b0fb609%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-19T02:47:45Z. Source state: Current. Version fingerprint: 3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd.
     How it applies: Application number of the label read, NDA022387.
  2. Background: openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism (Regulator, edition The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22cbc31ab1-a80f-4b50-a3b1-39910b0fb609%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-19T02:47:45Z. Source state: Current. Version fingerprint: 3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd.
     How it applies: Effective date of the label text read, 20260414.
  3. Supports: openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism (Regulator, edition The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22cbc31ab1-a80f-4b50-a3b1-39910b0fb609%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-19T02:47:45Z. Source state: Current. Version fingerprint: 3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd.
     How it applies: Label passage quoted in the research quote table (Q-K30-TRE-TY-03, Q-K30-TRE-TY-05, Q-K30-TRE-TY-06).

## Connected pages

- Treprostinil is a prostacyclin vasodilator in RxClass spelling (FDA established pharmacologic class): Prostacyclin pathway drugs (`cardio:prostacyclin-pathway-drugs`)
- FDA label for the Remodulin injection lists pulmonary arterial hypertension (WHO Group 1), to diminish symptoms associated with exercise, as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-remodulin-label-indications` and its context]
- FDA label for the Remodulin injection separately lists patients who require transition from epoprostenol as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-remodulin-label-transition` and its context]
- FDA label for the Tyvaso inhalation solution lists pulmonary arterial hypertension (WHO Group 1), to improve exercise ability, as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-tyvaso-label-pah` and its context]
- FDA label for the Tyvaso inhalation solution separately lists pulmonary hypertension associated with interstitial lung disease (WHO Group 3) as an indication: Pulmonary hypertension (`cardio:pulmonary-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-tyvaso-label-ph-ild` and its context]
- FDA label for the Orenitram tablets lists pulmonary arterial hypertension (WHO Group 1), to delay disease progression and to improve exercise capacity, as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-orenitram-label-pah` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: 69b9164487a54e6855c1ec2c62f078bb13729a4a2c4a9eec80dd893797684bcc
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
